ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2020
Early Experience With Meropenem-Vaborbactam for Treatment of Carbapenem-resistant Enterobacteriaceae Infections.
Erratum issuedAbstract read
In one paragraph
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 59 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Systematic Review and Meta-Analysis of Clinical Efficacy and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections.International journal of molecular sciences · 2024Pooled it
- Comparative outcomes of ceftazidime-avibactam versus meropenem-vaborbactam for KPC-producing Enterobacterales infections.Antimicrobial agents and chemotherapy · 2026Article
- Complete genome sequences of KPC-producingMicrobiology resource announcements · 2026Article
- Aminoglycosides enhance meropenem/vaborbactam activity against KPC-producingAntimicrobial agents and chemotherapy · 2026Article
- Treatment of central nervous system infections caused byFrontiers in medicine · 2026Review
- Unlocking potentials: the impact of meropenem, meropenem-vaborbactam, and ceftazidime-avibactam in combating carbapenem-resistantAntimicrobial agents and chemotherapy · 2025Article
- Emergence ofbioRxiv : the preprint server for biology · 2025Article
- Identifying drivers of β-lactam/β-lactamase inhibitor resistance emergence and spread before their clinical deployment.medRxiv : the preprint server for health sciences · 2025Article
- Population pharmacokinetics of meropenem-vaborbactam in acutely ill hospitalized patients with various degrees of renal dysfunction including continuous renal replacement therapy.Antimicrobial agents and chemotherapy · 2025Article
- Breaking Through Resistance: A Comparative Review of New Beta-Lactamase Inhibitors (Avibactam, Vaborbactam, Relebactam) Against Multidrug-Resistant Superbugs.Antibiotics (Basel, Switzerland) · 2025Review
- Meropenem-Vaborbactam for Treatment of Carbapenem-Resistant Enterobacterales: A Narrative Review of Clinical Practice Evidence.Infectious diseases and therapy · 2025Review
- Newly developed antibiotics against multidrug-resistant and carbapenem-resistant Gram-negative bacteria: action and resistance mechanisms.Archives of microbiology · 2025Review
- Near-Infrared Spectrometry as a Tool for Screening Meropenem for Quality.Contact in context · 2025Article
- National Cohort of Compassionate Use of Meropenem-Vaborbactam: No Benefit over Meropenem forAntibiotics (Basel, Switzerland) · 2024Article
- Novel Antibiotics for Gram-Negative Nosocomial Pneumonia.Antibiotics (Basel, Switzerland) · 2024Review
- Outcomes and Predictors of Mortality in Patients With KPC-Kp Infections Treated With Meropenem Vaborbactam: An Observational Multicenter Study.Open forum infectious diseases · 2024Article
- Real-world experience with meropenem/vaborbactam for the treatment of infections caused by ESBL-producing Enterobacterales and carbapenem-resistant Klebsiella pneumoniae.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2024Article
- Adequacy of the Dosing and Infusion Time of Ceftazidime/Avibactam for the Treatment of Gram-Negative Bacterial Infections: A PK/PD Simulation Study.Infection and drug resistance · 2024Article
- New Antibiotics Against Multidrug-Resistant Gram-Negative Bacteria in Liver Transplantation: Clinical Perspectives, Toxicity, and PK/PD Properties.Transplant international : official journal of the European Society for Organ Transplantation · 2024Review
- Meropenem/Vaborbactam: β-Lactam/β-Lactamase Inhibitor Combination, the Future in Eradicating Multidrug Resistance.Antibiotics (Basel, Switzerland) · 2023Review
Corrections and comments
- Erratum issuedErratum.2020
Authors and funding
11 authors.
Ryan K ShieldsDepartment of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Erin K McCrearyAntibiotic Management Program, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
Rachel V MariniAntibiotic Management Program, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
Ellen G KlineDepartment of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Chelsea E JonesDepartment of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Binghua HaoDepartment of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Liang ChenHackensack-Meridian Health Center for Discovery and Innovation, Nutley, New Jersey, USA.
Barry N KreiswirthHackensack-Meridian Health Center for Discovery and Innovation, Nutley, New Jersey, USA.
Yohei DoiDepartment of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Cornelius J ClancyDepartment of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
M Hong NguyenDepartment of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Funding
Therapeutics for drug-resistant bacteria: aryl myxopyronins and arylalkylcarboxamido phloroglucinolsU19AI142731 · NIAID · HACKENSACK UNIVERSITY MEDICAL CENTER · PI PERLIN, DAVID S · 2019 to 2023
$33.9MThe molecular basis of the epidemic blaKPC gene KlebsiellaR01AI090155 · NIAID · UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL · PI KREISWIRTH, BARRY NEAL · 2011 to 2021
$7.2MColistin-resistant Acinetobacter baumanniiR01AI104895 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DOI, YOHEI, ERNST, ROBERT K · 2014 to 2024
$4.2MCaspofungin pharmacokinetics-pharmacodynamics during intra-adbominal candidiasisK08AI114883 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SHIELDS, RYAN K · 2015 to 2019
$858kMicrobiome and host response signatures for pneumonia among lung transplant recipientsR21AI126157 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CLANCY, CORNELIUS J · 2016 to 2017
$468kStudy Network of Acinetobacter as a Carbapenem-Resistant Pathogen (SNAP)R21AI135522 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DOI, YOHEI · 2018 to 2019
$460kUnraveling colistin resistance in Klebsiella pneumoniaeR21AI135250 · NIAID · RBHS-NEW JERSEY MEDICAL SCHOOL · PI KREISWIRTH, BARRY NEAL · 2018 to 2019
$460kChromosomal and plasmid contributions to colistin resistance and virulence in KPC-producing Klebsiella pneumoniaeR21AI128338 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI NGUYEN, M. HONG THI · 2017 to 2018
$444kUse of site-specific pharmacokinetics to optimize antibiotic combinations and prevent the emergence of resistance against CRER21AI151363 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SHIELDS, RYAN K · 2021 to 2022
$431kCandida albicans regulatory pathways contributing to intra-abdominal candidiasisR21AI144390 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CLANCY, CORNELIUS J · 2019 to 2020
$427kMechanisms of ceftazidime-avibactam susceptibility and resistance among Enterobacteriaceae expressing variant KPCsR21AI142049 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CLANCY, CORNELIUS J · 2019 to 2020
$412kCharacterization and suppression of resistance to new CRE agentsR03AI144636 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SHIELDS, RYAN K · 2019 to 2020
$157kNIAID NIH HHS K08 AI114883NIAID NIH HHS R01 AI090155NIAID NIH HHS R01 AI104895NIAID NIH HHS R03 AI144636NIAID NIH HHS R21 AI126157NIAID NIH HHS R21 AI128338NIAID NIH HHS R21 AI135250NIAID NIH HHS R21 AI135522NIAID NIH HHS R21 AI142049NIAID NIH HHS R21 AI144390NIAID NIH HHS R21 AI151363NIAID NIH HHS U19 AI142731
Abstract
Twenty patients with carbapenem-resistant Enterobacteriaceae infections were treated with meropenem-vaborbactam. Thirty-day clinical success and survival rates were 65% (13/20) and 90% (18/20), respectively. Thirty-five percent of patients had microbiologic failures within 90 days. One patient developed a recurrent infection due to meropenem-vaborbactam-nonsusceptible, ompK36 porin mutant Klebsiella pneumoniae.
Indexed as
Carbapenem-Resistant EnterobacteriaceaeEnterobacteriaceae InfectionsAnti-Bacterial AgentsBacterial Proteinsbeta-LactamasesBoronic AcidsHumansKlebsiella pneumoniaeMeropenemMicrobial Sensitivity TestsAnti-Bacterial AgentsBacterial Proteinsbeta-LactamasesBoronic AcidsMeropenemvaborbactamKPCmeropenemporinresistancevaborbactam
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.